IMMP - プリマ・バイオメッド (Immutep Limited) プリマ・バイオメッド

 IMMPのチャート


 IMMPの企業情報

symbol IMMP
会社名 Immutep Ltd (プリマ・バイオメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   プリマ・バイオメッドはオ―ストラリアのバイオ医薬品会社。がん治療用の免疫療法医薬品の開発に従事する。主要パイプラインは、T細胞免疫反応の調節に重要な役割を果たすLAG-3の免疫制御システムを基にする。臨床段階の医薬品の一つは、T細胞免疫刺激因子(APC活性化因子)の「IMP321」、卵巣がん治療用の「CVac」である。本社はシドニ―。   Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
本社所在地 Level 12 95 Pitt Street Sydney New South Wales 2000 AUS
代表者氏名
代表者役職名
電話番号
設立年月日 31898
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 17人
url www.primabiomed.com.au
nasdaq_url https://www.nasdaq.com/symbol/immp
adr_tso 7379595
EBITDA EBITDA ー
終値(lastsale) 3.2
時価総額(marketcap) 23614704
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 IMMPのテクニカル分析


 IMMPのニュース

   Immutep (ASX:IMM) 1H20 results & outlook  2020/03/11 04:42:04 Finance News Network
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
   Immutep (ASX:IMM) reports positive trial data  2019/11/06 01:02:09 Finance News Network
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Immutep (ASX:IMM) 1H20 results & outlook  2020/03/11 04:42:04 Finance News Network
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
   Immutep (ASX:IMM) reports positive trial data  2019/11/06 01:02:09 Finance News Network
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Immutep (ASX:IMM) 1H20 results & outlook  2020/03/11 04:42:04 Finance News Network
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
   Immutep (ASX:IMM) reports positive trial data  2019/11/06 01:02:09 Finance News Network
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.

 関連キーワード  (― 米国株 プリマ・バイオメッド IMMP Immutep Limited)

 twitter  (公式ツイッターやCEOツイッターなど)